Victory Square Health Provides a Progress Update on its Covid-19 Test
Company announces initial 2 Million (2,000,000) orders
VANCOUVER, British Columbia, Sept. 20, 2020 (GLOBE NEWSWIRE) — Victory Square Health Inc. (“VS Health” or the “Company“) – a portfolio company of Victory Square Technologies Inc. (“Victory Square“) (CSE:VST) (OTC:VSQTF) (FWB:6F6) announced today that it received 2 Million (2,000,000) in orders of its Safetest Covid-19™ test in Brazil. Safetest Covid-19™ test enables the user to verify whether one is currently infected, has been infected or has never been infected with Covid-19. The Company this past month has:
Company received 2 Million (2,000,000) in orders for its Safetest Covid-19™ test in Brazil.
VS Health received the CE designation from the EU competent authority of Belgium for Safetest Elisa antibody test for distribution, sale, and usage throughout the 27 countries in the European Union.
VS Health received Brazilian ANIVSA approval for Safetest ELISA antibody test for distribution, sale, and usage throughout Brazil and export to Mercosur Countries (Argentina, Paraguay, Uruguay and Venezuela)
VS Health received USDA permission to commence marketing, sales and distribution of Safetest Covid-19™ Antibody Elisa Test under EUA.
VS Health was the first company to be approved in the Ideiagov program supported by the São Paulo State Government for immediate trials and application in the State.
VS Health increased monthly production of Covid-19 Rapid Tests by an additional 5,000,000 Test Kits to meet increased demand.
Safetest Covid-19™ IgG /IgM has demonstrated to the U.S. FDA, Brazilian, and European Union authorities 93.3% sensitivity and 98.7% specificity.
The Company continues to present its product for and receive new approvals from Health Authorities and Governments globally. Victory Square Health’s strategy is to receive ongoing global approvals from Governments followed by the Company’s implementation of immediate supply, manufacturing and distribution channels being set up with new partners in those approved jurisdictions/countries for rapid manufacturing, distribution and sales of its product.
“The school session in Brazil commences in October and full compliance and Covid-19 testing is a top priority and thus demand for our accurate and safe testing product has required our Company to immediately seek additional manufacturing channels for Brazil alone,” said Safetest CEO Felipe Peixoto. Peixoto continued, “Key talks are underway with leading manufacturing partners particularly in North America, Europe, and India to ramp up capacity and increase supply channels to meet the increased demand in those regions and on our Company for our proven product.”
The Company is currently engaging industries including but not limited to retail, hospitality, manufacturing, pharmaceutical, correctional facilities, casinos, sport, policing, first-responder, border services, education, transportation, military, government, and more. These industries and associations are important partners for the Company to align with for ongoing adoption, sales, and distribution channels.
Victory Square Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient’s care and improve health outcomes. Its first product, the Leishmaniasis Rapid Test, was developed in partnership with the UFMG, Federal University of Minas Gerais. Safetest capitalized upon its expertise in the subject to develop other antibody-based tests and a robust R&D pipelines of diagnostic kits for Hansen’s Disease, Brucellosis, HTLV and Blood samples screening tests.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
Check out VictorySquare.com and sign up to VST’s official newsletter at www.VictorySquare.com/newsletter.
On behalf of the board,
Shafin Diamond Tejani
Chief Executive Officer
Victory Square Technologies
For further information about the Company, please contact:
Investor Relations Contact – Alex Tzilios
Email: [email protected]
Media Relations Contact – Howard Blank, Director
Email: [email protected]
ABOUT VICTORY SQUARE TECHNOLOGIES INC.
Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth. The result: rapid scale-up and monetization, with a solid track record of public and private exits.
VST’s sweet spot is the cutting-edge tech that’s shaping the 4th Industrial Revolution. Our portfolio consists of 20 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.
What we do differently for startups
VST isn’t just another investor. With real skin in the game, we’re committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you’ll scale and be ready to monetize.
What we do differently for investors
VST is a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).
For investors, we offer early-stage access to the next unicorns before they’re unicorns.
Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies. Because we focus on market-ready solutions that scale quickly, we’re able to provide strong and stable returns while also tapping into emerging global trends with big upsides. For more information, please visit www.victorysquare.com.
Forward Looking Statement
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.